Importantly, overly positive interpretation of the study data is misleading to patients and must be avoided, as the current data simply do not warrant application of DCVax-L in patients with newly diagnosed or recurrent glioblastoma. Our mission is not to give more treatments to patients but to deliver treatments that improve outcome, based on solid evidence and not speculation.